Altered anterior default mode network dynamics in progressive multiple sclerosis

Giulia Bommarito; Anjali Tarun; Younes Farouj; Maria Giulia Preti; Maria Petracca; Amgad Droby; Mohamed Mounir El Mendili; Matilde Inglese; Dimitri Van De Ville

doi:10.1101/2020.11.26.20238923

Abstract

Background Modifications in brain function remain relatively unexplored in progressive multiple sclerosis (PMS), despite their potential to provide new insights into the pathophysiology of this disease stage.

Objectives To characterize the dynamics of functional networks at rest in patients with PMS, and the relation with clinical disability.

Methods Thirty-two patients with PMS underwent clinical and cognitive assessment. The dynamic properties of functional networks, retrieved from transient brain activity, were obtained from patients and 25 healthy controls (HC). Sixteen HC and 19 patients underwent a one-year follow-up clinical and imaging assessment. Differences in the dynamic metrics between groups, their longitudinal changes, and the correlation with clinical disability were explored.

Results PMS patients, compared to HC, showed a reduced dynamic functional activation of the anterior default mode network (aDMN) and its opposite-signed coactivation with the executive-control network, at baseline and follow-up. Processing speed and visuo-spatial memory negatively correlated to aDMN dynamic activity. The anti-coupling between aDMN and auditory/sensory-motor network, temporal-pole/amygdala or salience networks were differently associated to separate cognitive domains.

Conclusion Patients with PMS presented an altered aDMN functional recruitment and anti-correlation with ECN. The aDMN dynamic functional activity and interaction with other networks explained cognitive disability.

Competing Interest Statement

Giulia Bommarito, Anjali Tarun, Younes Farouj, Maria Giulia Preti, Maria Petracca, Amgad Droby, Mohamed Mounir El Mendili, and Dimitri Van De Ville have nothing to disclose. Matilde Inglese is currently receiving a grant from Teva Neuroscience.

Funding Statement

G. Bommarito was supported by a research fellowship FISM-Fondazione Italiana Sclerosi Multipla, Cod.: 2017/B/2 and financed or co-financed with the "5 per mille" public funding. A. Tarun and Y. Farouj were supported by the Swiss National Science Foundation under the Project Grant 205321-163376.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai. Written informed consent was obtained from all participants.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes